Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Authors

Thibault de la Motte Rouge, Clémentine Vabre, Hélène Denis, Ester Alessandrini, Ludiane Gauthier, Aurélie Schmidt, Gaëlle Nachbaur, Florence Joly

Published in

Bulletin du cancer. Jun 19, 2026. Epub Jun 19, 2026.

Abstract

The MOONBEAM retrospective cohort study examined epidemiology, treatment patterns, and outcomes in patients with endometrial cancer (EC) in France.
Data were obtained from the National Healthcare Database System (SystèmeNational desDonnées deSanté) from 2016-2021. Patients first hospitalized for EC or with first inscription on the Long-Term Disease list during the study period formed an incident EC cohort. A second cohort comprising patients with initial metastatic and/or recurrent EC was also analyzed. Endpoints included annual incidence and prevalence of EC, baseline characteristics, treatment patterns, overall survival (OS), and time to next treatment or death (TTNTD).
Of 60,083 patients in the incident EC cohort (median follow-up 2.0 years; median age 70 years), 23,060 met criteria for the initial metastatic and/or recurrent EC cohort (median follow-up 1.2 years; median age 71 years). Sociodemographic characteristics and comorbidities were similar between cohorts. In first line, 45.3% of the incident EC cohort and 7.4% of the metastatic/recurrent cohort underwent surgery alone, while 5.2% and 31.2%, respectively, received chemotherapy. Chemotherapy alone was the most frequent intervention in both cohorts. Median OS and TTNTD from index date were both not reached in the incident EC cohort, and 2.3 and 1.1 years, respectively, in the metastatic/recurrent EC cohort. At 2 years of follow-up, 21% of patients in the incident EC cohort and 37% in the metastatic/recurrent EC cohort had switched to second-line treatment.
The MOONBEAM study highlights the need for improved first-line treatments for metastatic and/or recurrent EC.

PMID:
42321049
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.